Prosecution Insights
Last updated: August 17, 2026
Application No. 18/893,545

SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS

Non-Final OA §101§112§DP
Filed
Sep 23, 2024
Priority
Feb 08, 2022 — continuation of 12/595,247 +1 more
Examiner
ROBINSON, MIKHAIL O'DONNEL
Art Unit
Tech Center
Assignee
Bayer Aktiengesellschaft
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
1y 5m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
73 granted / 124 resolved
-1.1% vs TC avg
Strong +42% interview lift
Without
With
+41.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
47 currently pending
Career history
160
Total Applications
across all art units

Statute-Specific Performance

§101
5.3%
-34.7% vs TC avg
§103
40.9%
+0.9% vs TC avg
§102
21.9%
-18.1% vs TC avg
§112
22.1%
-17.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 124 resolved cases

Office Action

§101 §112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claim 11 is rejected under 35 U.S.C. 101 because the claimed invention lacks patentable utility. The use of the phrase “Use of” makes it unclear of which statutory class the claim falls under. The claim language set no statutory class of a method of use or composition of matter. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 11 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 11, the phrase "Use of" renders the claim indefinite because it is unclear which statutory class the claim falls onto. If they are meant to be a method, an active step is missing. If they are meant to be a composition of matter, it is unclear if the “use” is a future intended use. The claim refers to a use of the compound without setting the limitation for the intended use of compound Formula (I). Double Patenting A rejection based on double patenting of the “same invention” type finds its support in the language of 35 U.S.C. 101 which states that “whoever invents or discovers any new and useful process... may obtain a patent therefor...” (Emphasis added). Thus, the term “same invention,” in this context, means an invention drawn to identical subject matter. See Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957). A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101. Claims 15-21 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-3 and 9-11 of copending Application No. 18256650 (reference application). Copending ‘650 is of the same invention of compound Formula (I) PNG media_image1.png 199 172 media_image1.png Greyscale or salt thereof, solvates thereof or solvates of salts thereof to treat a condition selected from the same list of claimed conditions. This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented. Claims 15-21 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 9, 11 and 13 of prior U.S. Patent No. 12595247. U.S ‘247 is of the same invention of compound Formula (I) PNG media_image2.png 273 218 media_image2.png Greyscale or salt thereof, solvates thereof or solvates of salts thereof to treat a condition selected from the list of the same claimed conditions. This is a statutory double patenting rejection. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MIKHAIL O'DONNEL ROBINSON whose telephone number is (571)270-0777. The examiner can normally be reached Monday-Friday 7:30am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. MIKHAIL O'DONNEL. ROBINSON Examiner Art Unit 1627 /MIKHAIL O'DONNEL ROBINSON/Examiner, Art Unit 1627 /SARAH PIHONAK/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Sep 23, 2024
Application Filed
Jul 17, 2026
Non-Final Rejection mailed — §101, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12703702
PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF
4y 3m to grant Granted Aug 11, 2026
Patent 12691094
USE OF CRASSIFOLIN A IN PREPARATION OF DRUG FOR PROMOTING MITOPHAGY AND TREATING NEURODEGENERATIVE DISEASES
2y 11m to grant Granted Jul 28, 2026
Patent 12691085
CANCER TREATMENT COMPOSITION AND METHOD
3y 1m to grant Granted Jul 28, 2026
Patent 12686686
DAPHNANE DITERPENOID RESISTANT TO PROSTATE CANCER AND PREPARATION METHOD THEREOF
3y 6m to grant Granted Jul 21, 2026
Patent 12673954
BENZOFURAN COMPOUNDS AS STING AGONISTS
2y 11m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+41.5%)
3y 4m (~1y 5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 124 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month